Prognostic significance of baseline low-density lipoprotein cholesterol in patients undergoing coronary revascularization; A report from the CREDO-Kyoto registry
Author:
Kanenawa KenjiORCID, Yamaji KyoheiORCID, Morimoto TakeshiORCID, Yamamoto KoORCID, Domei Takenori, Hyodo Makoto, Shiomi HirokiORCID, Furukawa YutakaORCID, Nakagawa YoshihisaORCID, Kadota Kazushige, Watanabe HirotoshiORCID, Yoshikawa YusukeORCID, Tada Tomohisa, Tazaki Junichi, Ehara Natsuhiko, Taniguchi RyojiORCID, Tamura ToshihiroORCID, Iwakura Atsushi, Tada Takeshi, Suwa Satoru, Toyofuku Mamoru, Inada TsukasaORCID, Kaneda KazuhisaORCID, Ogawa Tatsuya, Takeda Teruki, Sakai Hiroshi, Yamamoto Takashi, Tambara Keiichi, Esaki Jiro, Eizawa Hiroshi, Yamada Miho, Shinoda Eiji, Nishizawa Junichiro, Mabuchi Hiroshi, Tamura Nobushige, Shirotani Manabu, Nakayama Shogo, Uegaito Takashi, Matsuda Mitsuo, Takahashi Mamoru, Inoko Moriaki, Kanemitsu Naoki, Tamura Takashi, Ishii Kazuhisa, Nawada Ryuzo, Onodera Tomoya, Ohno Nobuhisa, Koyama Tadaaki, Tsuneyoshi Hiroshi, Sakamoto Hiroki, Aoyama Takeshi, Miki Shinji, Tanaka Masaru, Sato Yukihito, Yamazaki Fumio, Hanyu Michiya, Soga YoshiharuORCID, Komiya Tatsuhiko, Minatoya KenjiORCID, Ando KenjiORCID, Kimura TakeshiORCID
Abstract
AbstractBackgroundThe impact of very low baseline levels of low-density lipoprotein cholesterol (LDL-C) on patients with coronary artery disease remains unclear. Therefore, we aimed to investigate the baseline characteristics and clinical outcomes of patients with low baseline LDL-C levels who had undergone coronary revascularization.MethodsWe enrolled 39439 patients of the pooled population from the CREDO-Kyoto registries Cohorts 1, 2, and 3. After excluding 6306 patients with missing baseline LDL-C data, the study population consisted of 33133 patients who had undergone their first coronary revascularization. We assessed the risk for mortality and cardiovascular events according to quintiles of the baseline LDL-C levels.ResultsPatients in the very low LDL-C quintile (< 85 mg/dL) had more comorbidities than those in the other quintiles. Lower LDL-C levels were strongly associated with anemia, thrombocytopenia, and end-stage renal disease. The cumulative 4-year incidence of all-cause death increased as LDL-C levels decreased (very low: 19.4%, low: 14.5%, intermediate: 11.1%, high: 10.0%, and very high:9.2%; P<0.001), which was driven by both the early and late events. After adjusting for baseline characteristics, the adjusted risks of the very low and low LDL-C quintiles relative to the intermediate LDL-C quintile remained significant for all-cause death (very low: HR 1.29, 95% CI 1.16-1.44, P<0.001; low: HR 1.15, 95% CI 1.03-1.29, P=0.01). There were no significant interactions between the association of LDL-C level with all-cause death and subgroup factors, such as lipid-lowering treatment at index hospitalization, age, sex, acute myocardial infarction presentation, and study cohort. The excess adjusted risks of the lowest LDL-C quintile relative to the intermediate LDL-C quintile were significant for clinical outcomes such as cardiovascular death (HR 1.17, 95% CI 1.01-1.35), non-cardiovascular death (HR 1.35, 95% CI 1.15-1.60), sudden death (HR 1.44, 95% CI 1.01-2.06), and heart failure admission (HR 1.11 95% CI 1.01-1.22), while there was no excess risk for the lowest LDL-C quintile relative to the intermediate LDL-C quintile for myocardial infarction and stroke.ConclusionsLower baseline LDL-C levels were associated with more comorbidities and a significantly higher risk of death, regardless of cardiovascular or non-cardiovascular causes, in patients who underwent coronary revascularization.
Publisher
Cold Spring Harbor Laboratory
Reference40 articles.
1. Grundy SM , Stone NJ , Bailey AL , Beam C , Birtcher KK , Blumenthal RS , Braun LT , De Ferranti S , Faiella-Tommasino J , Forman DE , et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139. 2. Correction to: 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines;Circulation,2019 3. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk;Authors/Task Force M, Guidelines ESCCfP and Societies ESCNC;Atherosclerosis,2019 4. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials;The Lancet,2020 5. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials;The Lancet,2010
|
|